PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.61%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.88%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
7.07%
Gross profit growth of 7.07% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
23.00%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
18.46%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
42.27%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
42.25%
EPS growth of 42.25% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
42.25%
Diluted EPS growth of 42.25% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.01%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
22.22%
Dividend growth of 22.22% while Medical - Pharmaceuticals median is flat. Walter Schloss might appreciate at least a modest improvement.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
65.40%
10Y revenue/share CAGR 1.25-1.5x Medical - Pharmaceuticals median of 51.95%. Mohnish Pabrai would see if consistent reinvestment or product expansions drive this gap.
61.06%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 29.76%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
34.47%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 9.86%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
155.91%
Net income/share CAGR of 155.91% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
137.88%
Net income/share CAGR of 137.88% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
84.91%
3Y net income/share CAGR of 84.91% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
215.84%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 110.36% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
132.15%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 71.46%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
65.78%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 19.38%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-8.33%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-8.33%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
57.14%
3Y dividend/share CAGR of 57.14% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
34.92%
AR growth of 34.92% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
1.59%
Inventory growth of 1.59% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
5.03%
Asset growth of 5.03% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
4.95%
BV/share growth of 4.95% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-10.52%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
-45.14%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.